.JPG?ad=18503&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Unité d'Oncologie Moléculaire. Unité INSERM U453 [N. F., M-P. P., M. O., A. P.], Département d'Anatomie et de Cytologie Pathologiques [I. T., N. P.], and Département de Chirurgie Carcinologique [A-C. G., H. M., A. B.], Centre Léon Bérard, 69373 Lyon Cedex 08, France; Pharmacia Biotech AB, S-75182 Uppsala, Sweden [N. T., E. L., M. I.]; and Department of Molecular Biology and Genetics, Bilkent University, 06533 Ankara, Turkey [M. O.]
The most important subgroup of breast cancer patients for which reliable prognostic factors are needed are women without axillary lymph node involvement. Although overall, these patients have a good prognosis, it is known that 20–30% will experience a recurrence of the disease. To determine the prognostic significance of P53 tumor suppressor gene mutation, specimens from 113 primary breast cancers were evaluated for the presence of P53 alterations, as detected by cDNA sequencing of the entire coding sequence of the gene. The median follow-up for patients was 105 months. P53 gene mutation was an independent prognostic marker of early relapse and death. Our results suggest that P53 gene mutations could be an important factor to identify node-negative patients who have a poor prognosis in the absence of adjuvant therapy. Prospective studies should be designed to determine which therapy should be performed in this subgroup of patients.
1 To whom requests for reprints should be addressed, at Unité d'Oncologie Moléculaire, Unité INSERM U453, Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex 08, France.
Received 9/ 2/97. Accepted 2/ 2/98.
This article has been cited by other articles:
|
|
 |
|
  M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression Mol. Cell. Biol., November 15, 2005; 25(22): 10097 - 10110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Levy, G. Plu-Bureau, Y. Decroix, D. Hugol, W. Rostene, A. Kimchi, and A. Gompel Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis Clin. Cancer Res., May 1, 2004; 10(9): 3124 - 3130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Bataille, P Rummele, W Dietmaier, D Gaag, F Klebl, A Reichle, P Wild, F Hofstadter, and A Hartmann Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer Mol. Pathol., October 1, 2003; 56(5): 286 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Marchetti, K. Cannita, E. Ricevuto, F. De Galitiis, Z. C. Di Rocco, A. Tessitore, R. Bisegna, G. Porzio, G. P. De Rubeis, T. Ventura, et al. Prognostic value of p53 molecular status in high-risk primary breast cancer Ann. Onc., May 1, 2003; 14(5): 704 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas Ann. Onc., July 1, 2002; 13(7): 1108 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Conway, S. N. Edmiston, L. Cui, S. S. Drouin, J. Pang, M. He, C.-K. Tse, J. Geradts, L. Dressler, E. T. Liu, et al. Prevalence and Spectrum of p53 Mutations Associated with Smoking in Breast Cancer Cancer Res., April 1, 2002; 62(7): 1987 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Angèle, I. Treilleux, P. Tanière, G. Martel-Planche, M. Vuillaume, C. Bailly, A. Brémond, R. Montesano, and J. Hall Abnormal Expression of the ATM and TP53 Genes in Sporadic Breast Carcinomas Clin. Cancer Res., September 1, 2000; 6(9): 3536 - 3544. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. J. J. Berns, J. A. Foekens, R. Vossen, M. P. Look, P. Devilee, S. C. Henzen-Logmans, I. L. van Staveren, W. L. J. van Putten, M. Inganäs, M. E. M.-v. Gelder, et al. Complete Sequencing of TP53 Predicts Poor Response to Systemic Therapy of Advanced Breast Cancer Cancer Res., April 1, 2000; 60(8): 2155 - 2162. [Abstract] [Full Text]
|
|
|
|
|
|
M. Cuny, A. Kramar, F. Courjal, V. Johannsdottir, B. Iacopetta, H. Fontaine, J. Grenier, S. Culine, and C. Theillet Relating Genotype and Phenotype in Breast Cancer: An Analysis of the Prognostic Significance of Amplification at Eight Different Genes or Loci and of p53 Mutations Cancer Res., February 1, 2000; 60(4): 1077 - 1083. [Abstract] [Full Text]
|
|
|
|
|
|
B. Powell, R. Soong, B. Iacopetta, R. Seshadri, and D. R. Smith Prognostic Significance of Mutations to Different Structural and Functional Regions of the p53 Gene in Breast Cancer Clin. Cancer Res., February 1, 2000; 6(2): 443 - 451. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Brown and B. G. Wouters Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents Cancer Res., April 1, 1999; 59(7): 1391 - 1399. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
